Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta‐analysis
Top Cited Papers
- 1 March 2014
- journal article
- research article
- Published by Elsevier BV in Journal of Thrombosis and Haemostasis
- Vol. 12 (3), 320-328
- https://doi.org/10.1111/jth.12485
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Oral Apixaban for the Treatment of Acute Venous ThromboembolismNew England Journal of Medicine, 2013
- Extended Use of Dabigatran, Warfarin, or Placebo in Venous ThromboembolismNew England Journal of Medicine, 2013
- Do open label blinded outcome studies of novel anticoagulants versus warfarin have equivalent validity to those carried out under double-blind conditions?Thrombosis and Haemostasis, 2013
- Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary EmbolismNew England Journal of Medicine, 2012
- New oral anticoagulant drugs in cardiovascular diseaseThrombosis and Haemostasis, 2010
- Rivaroxaban – an oral, direct Factor Xa inhibitor – lessons from a broad clinical study programmeEuropean Journal of Haematology, 2009
- Idraparinux versus Standard Therapy for Venous Thromboembolic DiseaseNew England Journal of Medicine, 2007
- Treatment of Proximal Deep-Vein Thrombosis With the Oral Direct Factor Xa Inhibitor Rivaroxaban (BAY 59-7939)Cell Metabolism, 2007
- Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patientsJournal of Thrombosis and Haemostasis, 2005
- A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE IJournal of Thrombosis and Haemostasis, 2003